Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia

Solithromycin, a new macrolide, and the first fluoroketolide in clinical development, with activity against macrolide-resistant bacteria, was tested in 132 patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP) in a multicenter, double-blind, randomized phase 2 stu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Oldach, David, Clark, Kay, Schranz, Jennifer, Das, Anita, Craft, J Carl, Scott, Drusilla, Jamieson, Brian D., Fernandes, Prabhavathi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2013
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3716175/
https://ncbi.nlm.nih.gov/pubmed/23507282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00197-13
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak